9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

Estimated reading time: 1 min

Condition: Malignant Pleural Mesothelioma

Estimated Enrollment: 71

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Ph I: To determine the MTD of CBP501 + pemetrexed + cisplatin in patients with advanced solid tumors. Ph II: To evaluate the efficacy and safety profile of CBP501 + pemetrexed + cisplatin in patients with malignant pleural mesothelioma,  Ph I: To determine the recommended CBP501 dose for exploration in the phase II part,  Ph I: To undertake a preliminary characterization of the safety profile of the triplet combination, Ph I: Determine the pharmacokinetics of CBP501 when co-administered with cisplatin and pemetrexed and investigate any potential interactions

Interventions: pemetrexed, cisplatin and CBP501, pemetrexed and cisplatin

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: July 2012

Completion Date: November 2012

Last  Posted Date: December 21, 2012

Location: Mayo Clinic, Scottsdale, Arizona, United States

Website Link: https://ClinicalTrials.gov/show/NCT00700336

Was this article helpful?
Dislike 0